- Home
- PALI
PALI
Palisade Bio Inc.
as 12-18-2024 1:41pm EST
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 3.5M | IPO Year: | N/A |
| Target Price: | $23.00 | AVG Volume (30 days): | 3.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -13.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.38 - $22.35 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Palisade Bio Inc. News
PALI Breaking Stock News: Dive into PALI Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board
GlobeNewswire
5 days ago
Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
GlobeNewswire
6 days ago
Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
GlobeNewswire
15 days ago
Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects
GlobeNewswire
a month ago
Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)
GlobeNewswire
a month ago
Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit
GlobeNewswire
a month ago
Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108
GlobeNewswire
a month ago
Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)
Compare PALI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PALI Palisade Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.